Thermo Fisher Scientific has introduced the new fully customisable Gibco CTS Xenon Electroporation System, which enables large-scale cell therapy development and clinical manufacturing.

The new electroporation system enables gene modifications without using traditional viral vectors.

Using the Gibco CTS Xenon Electroporation System cell therapy, developers will have complete control of optimising various hard-to-transfect cell types and payloads.

Featuring programmable, flexible electroporation conditions, the device can be used as a standalone technology or integrated with the Gibco CTS Rotea Counterflow Centrifugation System as part of an automated cell therapy manufacturing workflow.

Thermo Fisher Scientific biosciences president Amy Butler said: “We launched the CTS Rotea System in 2020 as part of our strategy to deliver fit-for-purpose cell therapy solutions that can easily scale from development to commercialisation.

“Adding the CTS Xenon Electroporation System to our end-to-end workflow will help customers overcome manufacturing challenges that hinder production, enabling them to bring life-saving therapies to patients faster.”

The Xenon Electroporation System offers transfection performance in volumes of up to 2.5e9 cells in 25 mL in a sterile system. This enables quick non-viral transfection for clinical manufacturing applications.

Additionally, the CTS solution provides 90% gene knockout transfection and up to 80% cell viability, which supports scaling from the small-volume Neon Transfection System without the need to re-optimise electroporation parameters.

The CTS product line from Thermo Fisher is designed to work across the complete workflow, from cell isolation/activation to cell engineering and expansion, in order to address the manufacturing needs of cell therapy developers.

Recently, Thermo Fisher launched two new reverse transcription loop-mediated isothermal amplification-based solutions for simplifying surveillance of viral pathogens, including SARS-CoV-2.